Title | Author(s) | Issue date | ???itemlist.??? |
Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction | Briasoulis, E.; Karavasilis, V.; Tzamakou, E.; Piperidou, C.; Soulti, K.; Pavlidis, N. | 24-Nov-2015 | - |
Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in Patients with advanced gastrointestinal carcinomas: a phase I dose-finding and pharmacokinetic study | Bamias, A.; Syrigos, K.; Fountzilas, G.; Tzamakou, E.; Soulti, K.; Karavasilis, V.; Alamanos, Y.; Christodoulou, C.; Pavlidis, N. | 24-Nov-2015 | - |
Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel | Briasoulis, E.; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Soulti, K.; Piperidou, C.; Pavlidis, N. | 24-Nov-2015 | - |
Metronomic oral vinorelbine (MOVIN): a dose establishing translational and pharmacokinetic study in patients with metastatic refractory cancer | Briasoulis, E.; Tolis, C.; Pappas, P.; Marselos, M.; Nicolaides, C.; Nikiforidis, L.; Nikolaidou, M.; Siarabi, O.; Tzamakou, E.; Pavlidis, N. | 24-Nov-2015 | - |
Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study | Briasoulis, E.; Karavasilis, V.; Tzamakou, E.; Haidou, C.; Piperidou, C.; Pavlidis, N. | 24-Nov-2015 | - |
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group | Briasoulis, E.; Judson, I.; Pavlidis, N.; Beale, P.; Wanders, J.; Groot, Y.; Veerman, G.; Schuessler, M.; Niebch, G.; Siamopoulos, K.; Tzamakou, E.; Rammou, D.; Wolf, L.; Walker, R.; Hanauske, A. | 24-Nov-2015 | - |
Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes | Pentheroudakis, G.; Briasoulis, E.; Karavassilis, V.; Mauri, D.; Tzamakou, E.; Rammou, D.; Pavlidis, N. | 24-Nov-2015 | - |
Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program | Razis, E.; Skarlos, D.; Briasoulis, E.; Dimopoulos, M.; Fountzilas, G.; Lambropoulos, S.; Rigatos, S.; Kopterides, P.; Efstathiou, H.; Tzamakou, E.; Bakoyannis, C.; Pectasides, D.; Makatsoris, T.; Varthalitis, G.; Papadopoulos, S.; Kosmidis, P. | 24-Nov-2015 | - |
Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy | Pentheroudakis, G.; Pappas, P.; Golfinopoulos, V.; Fountzilas, G.; Nikolaidou, M.; Boumba, V. A.; Vougiouklakis, T.; Nikiforidis, L.; Tzamakou, E.; Siarabi, O.; Marselos, M.; Pavlidis, N. | 24-Nov-2015 | - |
Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration | Briasoulis, E.; Karavasilis, V.; Anastasopoulos, D.; Tzamakou, E.; Fountzilas, G.; Rammou, D.; Kostadima, V.; Pavlidis, N. | 24-Nov-2015 | - |
Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors | Briasoulis, E.; Pentheroudakis, G.; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Pavlidis, N. | 24-Nov-2015 | - |